"Tumor Cell" published the important results of the Chest Hospital team: breakthrough progress in immunotherapy for esophageal cancer
On October 12, the national key research and development plan "Construction of an Individualized Precision Diagnosis and Treatment System for Esophageal Cancer" undertaken by the team of Li Zhigang, deputy director of the Thoracic Surgery Department and Director of the Esophageal Subspecialty of Shanghai Chest Hospital, made important progress. The latest research results were among the top international oncology Published online in the scientific journal "Tumor Cell", with an impact factor of 50.3. Li Zhigang is the first corresponding author of the paper, and Dr. Liu Zhichao from the Department of Thoracic Surgery, Assistant Researcher Ma Ning and Dr. Yang Yang are the co-first authors. The research was also funded by the National Key Research and Development Program of the Ministry of Science and Technology, the National Natural Science Foundation of China, and the Shanghai Municipal Science and Technology Commission.
China is a country with a high incidence of esophageal cancer. According to WHO statistics, there are about 400,000 new cases of esophageal cancer and about 300,000 deaths every year in the world. China accounts for about half of the global cases and deaths every year. Among them, more than 90% are esophageal squamous cell carcinomas, and most patients are in the middle and late stages when diagnosed, and direct surgery has poor results.
In order to explore the efficacy of immunotherapy in patients with operable esophageal cancer, the Esophageal Surgery Department of Chest Hospital took the lead in launching the NICE study. This is one of the earliest registered clinical studies of neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer in the world, and relevant results have been published in authoritative thoracic surgery journals such as JTCVS. Based on the excellent results of the NICE study and multiple similar studies, in 2022, the CSCO esophageal cancer diagnosis and treatment guidelines have included the immune combination chemotherapy regimen as a level III recommendation for neoadjuvant treatment.
However, the current immunotherapy for esophageal cancer is not precise enough, and clinical biomarkers are still lacking to guide medication and predict efficacy. Based on the previous NICE research results, Li Zhigang's team conducted further translational research in collaboration with Su Jianzhong's team at Wenzhou Medical University, Liu Zhihua's team at the Cancer Hospital of the Chinese Academy of Medical Sciences, and Long Lingyun's team at the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, and systematically analyzed the efficacy of immunotherapy for esophageal squamous cell carcinoma. Cellular and molecular characteristics of diverse populations.
The study confirmed for the first time that SPRY1PD1CD8 T cells can be used as a reliable independent predictive marker for the clinical benefit of immunotherapy for esophageal squamous cell carcinoma. It also found that depleting precursor T cells can promote the activation of the tumor immune microenvironment, thereby enhancing the anti-tumor function, and providing a new basis for immunotherapy of esophageal cancer. Clinical benefit provides predictive value. This research result fills the gap in the research on the cellular molecular mechanisms of immunotherapy for esophageal cancer, has important clinical translation significance and prospects, and will provide new basis and direction for exploring more precise and effective immunotherapy strategies for esophageal squamous cell carcinoma.
!["Tumor Cell" published the important results of the Chest Hospital team: breakthrough progress in immunotherapy for esophageal cancer](https://a5qu.com/upload/images/89fd8219fcfc735b027145b1a497cbff.webp)